Obesity and NAFLD: Mechanisms and Therapeutics
Organizer(s): Rebecca A. Haeusler, Shingo Kajimura and Alexei KharitonenkovDate: February 23 - 27, 2020
Location: Fairmont Banff Springs, Banff, AB, Canada
For important information on the coronavirus, please click here
Energy metabolism underlies all facets of human health. With the rates of obesity and nonalcoholic fatty liver disease (NAFLD) surging, understanding how energy metabolism is governed in healthy and diseased states is of the utmost concern. The focus of this Keystone Symposia is to bring obesity and NAFLD disease researchers together to identify metabolic disease factors and future directions. Halting the progression of NAFLD into nonalcoholic steatohepatitis (NASH) is considered an unmet need in human health. Therefore, the conference program is designed to discuss both the regulatory elements driving the progression of obesity and NAFLD and the metabolic underpinnings of NASH. The program also includes sessions on metabolites, hormones, and cellular signaling pathways and features cutting edge therapeutic approaches for obesity and NASH. This conference will bring together scientists and physicians specializing in basic, translational, and clinical research, as well as industry scientists, to create a robust exchange of ideas on how to move the field forward.
Scholarship Deadline: October 23 2019
Discounted Abstract Deadline: October 23 2019
Abstract Deadline: November 21 2019
Discounted Registration Deadline: December 19 2019
Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email firstname.lastname@example.org if you are interested.
We gratefully acknowledge additional support from these exhibitors at this conference:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Novo Nordisk A/S
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Grant No. 1R13DK123897-01
Funding for this conference was made possible (in part) by 1R13DK123897-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.